Carfilzomib induced cardiotoxicity in a multiple myeloma patient
Abstract Proteasome inhibitors such as carfilzomib are indicated in multiple myeloma patients showing relapse and/or refractoriness of clonal activity. However, this therapy has been associated with a significant incidence of cardiotoxicity, especially in patients with known cardiovascular risk fact...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-09-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40959-020-00074-8 |